Durham-based Immunotherapy firm Grid Therapeutics injects $4.5M funding
Grid Therapeutics, a Durham-based biotechnology company developing the first human derived targeted immunotherapy for cancer, has raised more than $4.5 million of a $5 million equity offering, according to a filing with the U.S. Securities and Exchange Commission.
Read More
